Skip to main content
ASSURE TECH (HANGZHOU) CO., LTD. logo

ASSURE TECH (HANGZHOU) CO., LTD. — Investor Relations & Filings

Ticker · 688075 ISIN · CNE100004ZC0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 449 across all filing types
Latest filing 2024-09-19 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 688075

About ASSURE TECH (HANGZHOU) CO., LTD.

https://www.diareagent.com/

Assure Tech (Hangzhou) Co., Ltd. is a biotechnology enterprise specializing in the research, development, and manufacturing of in vitro diagnostic (IVD) reagents and clinical testing instruments. The company focuses on rapid diagnostic tests and Point of Care Testing (POCT) solutions across various medical fields, including infectious diseases, drug of abuse screening, oncology, cardiac markers, and fertility. Utilizing advanced lateral flow immunoassay technology, Assure Tech provides diagnostic tools designed for accuracy and efficiency in clinical and laboratory settings. The company adheres to international quality standards, maintaining ISO 13485 certification and obtaining regulatory clearances such as FDA and CE marks for its product range. Through its integrated R&D and production infrastructure, Assure Tech supplies a diverse portfolio of diagnostic products to a global customer base.

Recent filings

Filing Released Lang Actions
上海市锦天城律师事务所关于杭州安旭生物科技股份有限公司2024年第二次临时股东大会法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening and procedures of the 2024 second extraordinary general meeting (临时股东大会) of Hangzhou Anxu Biotechnology Co., Ltd. It details the legality of the meeting's convocation, attendance, voting procedures, and results. The document does not contain financial statements or management discussion but focuses on the legal compliance and validity of the shareholder meeting and its resolutions. The document length is 3891 characters, which is relatively short and consistent with a legal opinion or announcement rather than a full report. This type of document is best classified as a Declaration of Voting Results & Voting Rights Announcements (DVA), as it reports on the voting results and legality of a shareholder meeting.
2024-09-19 Chinese
安旭生物关于2024年限制性股票激励计划内幕信息知情人买卖公司股票情况的自查报告
Regulatory Filings Classification · 95% confidence The document is a self-inspection report regarding insider trading activities related to a 2024 restricted stock incentive plan. It details the scope, procedures, and findings of the investigation into whether insiders traded company stock during a specified period. The document is an announcement of the results of an internal compliance check rather than a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial data. It is also not a regulatory certification or a proxy solicitation. The content fits best under Regulatory Filings (RNS) as it is a compliance-related disclosure that does not fit other specific categories.
2024-09-19 Chinese
安旭生物关于召开2024年半年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of a 2024 half-year performance explanation meeting (业绩说明会) for investors. It references the company's 2024 half-year report already published on August 30, 2024, but this document itself does not contain financial data or the report. Instead, it provides information on the meeting time, location, participation method, and contact details. The document is short (1480 characters) and serves as a notice for an upcoming investor presentation event rather than the report or transcript itself. Therefore, it fits best under Investor Presentation (IP) as it is a detailed presentation for investors focusing on financials and company performance, even though the actual presentation will occur later. It is not a full transcript or the report itself, so it is not IR or CT. It is not a report publication announcement since it does not announce the report release but the meeting to discuss it.
2024-09-11 Chinese
安旭生物2024年第二次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as materials for the 2024 second extraordinary general meeting of shareholders of Hangzhou Anxu Biotechnology Co., Ltd. It contains detailed meeting notices, agenda, and multiple proposals to be voted on during the meeting, including cash management, profit distribution, and a restricted stock incentive plan. The content is focused on the meeting procedures, voting instructions, and proposal details for shareholder consideration. There is no financial statement or comprehensive financial report included, but rather the meeting materials and agenda for a shareholder meeting. This fits the definition of AGM Information (AGM-R), which includes presentations and materials shared during the Annual or Extraordinary General Meeting.
2024-09-11 Chinese
安旭生物监事会关于公司2024年限制性股票激励计划首次授予激励对象名单的核查意见及公示情况说明
Regulatory Filings Classification · 95% confidence The document is a public announcement by the supervisory board of Hangzhou Anxu Biotechnology Co., Ltd. regarding the verification and public disclosure of the initial list of incentive recipients under the company's 2024 restricted stock incentive plan. It includes details about the internal and external disclosure process, legal compliance checks, and confirmation that the incentive recipients meet regulatory and company requirements. The document is not a financial report, earnings release, or management discussion but rather a regulatory announcement related to the company's stock incentive plan and compliance with relevant laws and regulations. It does not contain financial statements or detailed financial data. Given the nature of the content, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-09-09 Chinese
民生证券股份有限公司关于杭州安旭生物科技股份有限公司2024年半年度持续督导跟踪报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2024年半年度持续督导跟踪报告" which translates to "2024 Semi-Annual Continuous Supervision Follow-up Report." It is issued by the sponsor institution (民生证券股份有限公司) responsible for ongoing supervision of the listed company (杭州安旭生物科技股份有限公司). The content includes detailed descriptions of supervision activities, risk factors, financial data for the first half of 2024, core competitiveness, R&D progress, use of raised funds, and shareholding information. The document contains substantive financial data and analysis for the half-year period ending June 30, 2024, including income, profit, cash flow, and other key financial metrics. It is not a brief announcement or a certification letter but a comprehensive report covering a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-09-09 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.